MX388694B - Compuestos neuroactivos y metodos de uso de los mismos. - Google Patents

Compuestos neuroactivos y metodos de uso de los mismos.

Info

Publication number
MX388694B
MX388694B MX2017004684A MX2017004684A MX388694B MX 388694 B MX388694 B MX 388694B MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 388694 B MX388694 B MX 388694B
Authority
MX
Mexico
Prior art keywords
methods
neuroactive compounds
sterol
subject
disorder
Prior art date
Application number
MX2017004684A
Other languages
English (en)
Other versions
MX2017004684A (es
Inventor
Botella Gabriel Martinez
James J Doherty
Michael C Quirk
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2017004684A publication Critical patent/MX2017004684A/es
Publication of MX388694B publication Critical patent/MX388694B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar un paciente que padece de un trastorno de síntesis de esterol o un trastorno de deficiencia de esterol, por ejemplo, síndrome Smith-Lemli-Opitz, el método comprende administrar al sujeto una cantidad efectiva de un compuesto que modula el receptor NMDA.
MX2017004684A 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos. MX388694B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
PCT/US2015/054551 WO2016057713A1 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017004684A MX2017004684A (es) 2017-06-30
MX388694B true MX388694B (es) 2025-03-20

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004684A MX388694B (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos.
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US20170304321A1 (es)
EP (1) EP3204011A4 (es)
JP (3) JP2017530982A (es)
KR (1) KR20170065637A (es)
CN (2) CN107405352A (es)
AU (2) AU2015330906A1 (es)
BR (1) BR112017007053A2 (es)
CA (1) CA2963938C (es)
IL (2) IL292465B2 (es)
MX (2) MX388694B (es)
MY (1) MY202135A (es)
PE (1) PE20170907A1 (es)
PH (1) PH12017500639A1 (es)
RU (1) RU2764702C2 (es)
SG (2) SG10202011773UA (es)
WO (1) WO2016057713A1 (es)
ZA (1) ZA201702545B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI816417B (zh) 2013-12-24 2023-09-21 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
HK1255500A1 (zh) * 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
WO2018026781A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
TW202444381A (zh) * 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059961A2 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US9737522B2 (en) * 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
KR20150110787A (ko) * 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
JP2016514967A (ja) * 2013-03-13 2016-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
EP4306114A1 (en) * 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) * 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
HK1255500A1 (zh) * 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法

Also Published As

Publication number Publication date
AU2015330906A1 (en) 2017-04-27
US20230218638A1 (en) 2023-07-13
MX2021011939A (es) 2021-11-03
WO2016057713A1 (en) 2016-04-14
MY202135A (en) 2024-04-05
EP3204011A4 (en) 2018-06-20
PH12017500639A1 (en) 2017-09-25
KR20170065637A (ko) 2017-06-13
RU2017115849A3 (es) 2019-05-15
IL251505B (en) 2022-05-01
SG10202011773UA (en) 2021-01-28
IL292465A (en) 2022-06-01
NZ730862A (en) 2024-01-26
AU2021200721A1 (en) 2021-03-04
JP2020196759A (ja) 2020-12-10
JP2017530982A (ja) 2017-10-19
AU2021200721B2 (en) 2023-06-01
CN112121171A (zh) 2020-12-25
JP2022033285A (ja) 2022-02-28
IL292465B2 (en) 2025-06-01
IL292465B1 (en) 2025-02-01
BR112017007053A2 (pt) 2018-06-19
RU2017115849A (ru) 2018-11-13
SG11201702799UA (en) 2017-05-30
RU2764702C2 (ru) 2022-01-19
CA2963938A1 (en) 2016-04-14
ZA201702545B (en) 2019-06-26
IL251505A0 (en) 2017-05-29
EP3204011A1 (en) 2017-08-16
CA2963938C (en) 2023-10-24
MX2017004684A (es) 2017-06-30
PE20170907A1 (es) 2017-07-12
CN107405352A (zh) 2017-11-28
US20170304321A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
BR112016014731A2 (pt) Anticorpos anti-baff
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
MX381276B (es) Moduladores de linfocitos t reguladores multivalentes.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
MX2020003224A (es) Moduladores de receptor nuclear.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
EA201491894A1 (ru) Способы лечения непереносимости лактозы
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
IL282254A (en) Compounds, compositions, and methods for modulating cdk9 activity
MX2014011103A (es) Moduladores del receptor x del higado.
IN2014KN02993A (es)
EA201691493A1 (ru) Замещенные n-арилпиридиноны
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов